ESTRO 37 Abstract book

S908

ESTRO 37

8 Hospital of the University of Pennsylvania, Radiation Oncology, Philadelphia, USA 9 Belgium, , Purpose or Objective Although there exist international guidelines for the use of radiotherapy (RT) in muscle-invasive bladder cancer (MIBC), there is still a gap between the optimal and actual use of RT. Therefore, this study investigated the opinions of radiation-oncologists, urologists and medical oncologists on the use of RT in primary, adjuvant and palliative setting for MIBC. In addition, possible barriers and facilitators for applying RT guidelines were examined. Material and Methods A web-based survey (aiming at radiation-oncologists, urologists and medical oncologists) was developed and pilot-tested at the University Hospital of Ghent. The survey was disseminated through different channels (EAU newsletter, IBIS group, Belgian College for Physicians in Radiation Oncology) and was conducted from November 18, 2016 to July 17, 2017. Different clinical cases were presented evaluating the place of primary, adjuvant and palliative RT. Also questions examining general information (e.g. country, type of hospital) and closed- ended questions on the use of guidelines, possible barriers and facilitators for using RT in MIBC were assessed. Results In total, 169 physicians (71 radiation-oncologists, 68 urologists and 30 medical oncologists) completed the survey. Detailed information on use of radiotherapy in the different clinical cases is presented in table 1. Guidelines most often followed were those from EAU (70%), NCCN (34%), institution (32%), ESMO (31%) and national guidelines (22%). Most reported reasons for non- adherence to guidelines were external barriers such as no referrals, cost/health economics (19%), no experience with RT for MIBC (13%) and negative experiences with RT in previous practice (13%). 37% always follow the guidelines and do not report barriers. Most often reported strategies to improve the awareness of existing guidelines are a compact summary of guidelines on the website of the national organization (54%), multidisciplinary oncological consultation (54%), an update of the existing guidelines by e-mail (53%), dissemination through symposia (44%) and a short overview of current trials by e-mail (39%).

mind the actual gap in RT utilization and predicted increase in patients requiring RT for MIBC in the future. Funding Kom op tegen kanker grant

Electronic Poster: Clinical track: Other

EP-1688 Low-dose radiotherapy in painful degenerative osteoarthritis: long-term efficacy and outcomes. R. Hernanz de Lucas 1 , A. Montero 2 , D. Candini 1 , E. Fernandez 1 , S. Sancho 1 1 Hospital Ramon y Cajal, radiation oncology, Madrid, Spain 2 Hospital Clara Campal .Sanchinarro, radiation oncology, madrid, Spain Purpose or Objective To evaluate the long-term efficacy of low-dose radiation treatment (RT) in painful arthrosis. Material and Methods From January-2006 to December-2016, 128 degenerative osteoarthritis of the knee (84%), shoulder (8%), hands (4%) and hip (4%) from 70 patients underwent low-dose RT for palliative pain control. Visual analogue scales (VASs; from 0 to 10) and the subjective score according to von Pannewitz (improved/no change/worsened) were used for recording the symptomatic changes. A RT dose of 6Gy with 6 fractions of 1.0Gy was delivered. The final outcome was assessed at least 6–8 weeks after completion of RT and in case of persisting pain or insufficient pain relief 6–12 weeks after the first RT course, a second RT series was recommended. Results This series included 57 women and 13 men, with a median age of 81 years (range: 42-91). The median pre- treatment value of VAS was 8 (range: 5-10). Fifty-eight painful sites underwent a second course of radiotherapy and median time interval between two treatments was 15 weeks (range: 8-68). With a median follow-up of 42 months (range: 2-118), median VAS at last visit was of 3 (range: 0-8). Median pain reduction for at least 3 months was reported in 74% (15-100%), median pain reduction for at least 12 months in 52% (18-100%). Von Pannewitz score resulted as “improved” in 89% of patients. No acute or chronic side effects were observed. Conclusion RT is an effective alternative for treatment of painful osteoarthritis with optimal response and low toxicity also in the long-term setting. EP-1689 Patterns of Intraosseous Recurrence After Stereotactic Body Radotherapy for Coxal Bone Metastasis K. Ito 1 , T. Shimizuguchi 1 , K. Nihei 1 , T. Furuya 1 , H. Ogawa 1 , K. Karasawa 1 1 Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Department Radiology MD., TOKYO, Japan Purpose or Objective To analyze the detailed pattern of intraosseous failure after stereotactic bodyradiation therapy (SBRT) for coxal bone metastasis. Material and Methods Patients treated with SBRT to coxal bone metastasis wereidentified by retrospective chart review. The SBRT

Conclusion There is a lot of controversy regarding the place of RT in MIBC, with a clear variation between oncology professionals and a dependence of tumor-and patient- related factors. Barriers and facilitators to use RT for MIBC were defined which should be addressed, keeping in